CytomX Therapeutics Details Phase 1 Trial Results For Colorectal Cancer Treatment
MT Newswires Live
Mar 16
CytomXTherapeutics (CTMX) said Monday a Phase 1 clinical trial evaluating varsetatug masetecan in patients with advanced colorectal cancer yielded confirmed response rates of up to 32%.
Patients receiving the 10-milligram per kilogram dose demonstrated an estimated median progression-free survival of 7.1 months, the company said.
The 8.6-milligram per kilogram cohort showed a 20% response rate alongside a 6.8-month estimated progression-free survival period, CytomX said.
The company also said severe diarrhea occurred in 10% of trial participants who received optimized preventative medications during the evaluation.
Shares of the company were up over 52% in Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.